Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy

Evolution over 12 years and predictors

Laura Bracciale, M. Colafigli, M. Zazzi, P. Corsi, P. Meraviglia, V. Micheli, R. Maserati, N. Gianotti, G. Penco, M. Setti, S. Di Giambenedetto, L. Butini, A. Vivarelli, M. Trezzi, A. De Luca

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretroviral therapy. Patients and methods A retrospective analysis was performed to assess the prevalence and correlates of TDR in Italy over time. TDR was defined as the presence of at least one of the mutations present in the surveillance drug resistance mutation (SDRM) list. Results: Among 1690 antiretroviral therapy-naive patients, the most frequent HIV subtypes were B (78.8%), CRF02_AG (5.6%) and C (3.6%). Overall, TDR was 15%. TDR was 17.3% in subtype B and 7.0% in non-B carriers (P <0.001). TDR showed a slight, although not significant, decline (from 16.3% in 1996-2001 to 13.4% in 2006-07, P = 0.15); TDR declined for nucleoside reverse transcriptase inhibitors (from 13.1% to 8.2%, P = 0.003) but remained stable for protease inhibitors (from 3.7% to 2.5%, P = 0.12) and non-nucleoside reverse transcriptase inhibitors (from 3.7% to 5.8%). TDR to any drug was stable in B subtype and showed a decline trend in non-B. In multivariable analysis, F1 subtype or any non-B subtype, compared with B subtype, and higher HIV RNA were independent predictors of reduced odds of TDR. Conclusions: Prevalence of TDR to nucleoside reverse transcriptase inhibitors seems to have declined in Italy over time. Increased prevalence of non-B subtypes partially justifies this phenomenon.

Original languageEnglish
Pages (from-to)607-615
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume64
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Drug Resistance
Italy
HIV-1
Reverse Transcriptase Inhibitors
Nucleosides
HIV
Mutation
Protease Inhibitors
RNA

Keywords

  • Decline
  • Drug-naive
  • Subtype

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy : Evolution over 12 years and predictors. / Bracciale, Laura; Colafigli, M.; Zazzi, M.; Corsi, P.; Meraviglia, P.; Micheli, V.; Maserati, R.; Gianotti, N.; Penco, G.; Setti, M.; Di Giambenedetto, S.; Butini, L.; Vivarelli, A.; Trezzi, M.; De Luca, A.

In: Journal of Antimicrobial Chemotherapy, Vol. 64, No. 3, 2009, p. 607-615.

Research output: Contribution to journalArticle

Bracciale, L, Colafigli, M, Zazzi, M, Corsi, P, Meraviglia, P, Micheli, V, Maserati, R, Gianotti, N, Penco, G, Setti, M, Di Giambenedetto, S, Butini, L, Vivarelli, A, Trezzi, M & De Luca, A 2009, 'Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors', Journal of Antimicrobial Chemotherapy, vol. 64, no. 3, pp. 607-615. https://doi.org/10.1093/jac/dkp246
Bracciale, Laura ; Colafigli, M. ; Zazzi, M. ; Corsi, P. ; Meraviglia, P. ; Micheli, V. ; Maserati, R. ; Gianotti, N. ; Penco, G. ; Setti, M. ; Di Giambenedetto, S. ; Butini, L. ; Vivarelli, A. ; Trezzi, M. ; De Luca, A. / Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy : Evolution over 12 years and predictors. In: Journal of Antimicrobial Chemotherapy. 2009 ; Vol. 64, No. 3. pp. 607-615.
@article{ab169e5585324ed29909e3be458ff347,
title = "Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: Evolution over 12 years and predictors",
abstract = "Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretroviral therapy. Patients and methods A retrospective analysis was performed to assess the prevalence and correlates of TDR in Italy over time. TDR was defined as the presence of at least one of the mutations present in the surveillance drug resistance mutation (SDRM) list. Results: Among 1690 antiretroviral therapy-naive patients, the most frequent HIV subtypes were B (78.8{\%}), CRF02_AG (5.6{\%}) and C (3.6{\%}). Overall, TDR was 15{\%}. TDR was 17.3{\%} in subtype B and 7.0{\%} in non-B carriers (P <0.001). TDR showed a slight, although not significant, decline (from 16.3{\%} in 1996-2001 to 13.4{\%} in 2006-07, P = 0.15); TDR declined for nucleoside reverse transcriptase inhibitors (from 13.1{\%} to 8.2{\%}, P = 0.003) but remained stable for protease inhibitors (from 3.7{\%} to 2.5{\%}, P = 0.12) and non-nucleoside reverse transcriptase inhibitors (from 3.7{\%} to 5.8{\%}). TDR to any drug was stable in B subtype and showed a decline trend in non-B. In multivariable analysis, F1 subtype or any non-B subtype, compared with B subtype, and higher HIV RNA were independent predictors of reduced odds of TDR. Conclusions: Prevalence of TDR to nucleoside reverse transcriptase inhibitors seems to have declined in Italy over time. Increased prevalence of non-B subtypes partially justifies this phenomenon.",
keywords = "Decline, Drug-naive, Subtype",
author = "Laura Bracciale and M. Colafigli and M. Zazzi and P. Corsi and P. Meraviglia and V. Micheli and R. Maserati and N. Gianotti and G. Penco and M. Setti and {Di Giambenedetto}, S. and L. Butini and A. Vivarelli and M. Trezzi and {De Luca}, A.",
year = "2009",
doi = "10.1093/jac/dkp246",
language = "English",
volume = "64",
pages = "607--615",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy

T2 - Evolution over 12 years and predictors

AU - Bracciale, Laura

AU - Colafigli, M.

AU - Zazzi, M.

AU - Corsi, P.

AU - Meraviglia, P.

AU - Micheli, V.

AU - Maserati, R.

AU - Gianotti, N.

AU - Penco, G.

AU - Setti, M.

AU - Di Giambenedetto, S.

AU - Butini, L.

AU - Vivarelli, A.

AU - Trezzi, M.

AU - De Luca, A.

PY - 2009

Y1 - 2009

N2 - Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretroviral therapy. Patients and methods A retrospective analysis was performed to assess the prevalence and correlates of TDR in Italy over time. TDR was defined as the presence of at least one of the mutations present in the surveillance drug resistance mutation (SDRM) list. Results: Among 1690 antiretroviral therapy-naive patients, the most frequent HIV subtypes were B (78.8%), CRF02_AG (5.6%) and C (3.6%). Overall, TDR was 15%. TDR was 17.3% in subtype B and 7.0% in non-B carriers (P <0.001). TDR showed a slight, although not significant, decline (from 16.3% in 1996-2001 to 13.4% in 2006-07, P = 0.15); TDR declined for nucleoside reverse transcriptase inhibitors (from 13.1% to 8.2%, P = 0.003) but remained stable for protease inhibitors (from 3.7% to 2.5%, P = 0.12) and non-nucleoside reverse transcriptase inhibitors (from 3.7% to 5.8%). TDR to any drug was stable in B subtype and showed a decline trend in non-B. In multivariable analysis, F1 subtype or any non-B subtype, compared with B subtype, and higher HIV RNA were independent predictors of reduced odds of TDR. Conclusions: Prevalence of TDR to nucleoside reverse transcriptase inhibitors seems to have declined in Italy over time. Increased prevalence of non-B subtypes partially justifies this phenomenon.

AB - Objectives: Transmitted HIV-1 drug resistance (TDR) can reduce the efficacy of first-line antiretroviral therapy. Patients and methods A retrospective analysis was performed to assess the prevalence and correlates of TDR in Italy over time. TDR was defined as the presence of at least one of the mutations present in the surveillance drug resistance mutation (SDRM) list. Results: Among 1690 antiretroviral therapy-naive patients, the most frequent HIV subtypes were B (78.8%), CRF02_AG (5.6%) and C (3.6%). Overall, TDR was 15%. TDR was 17.3% in subtype B and 7.0% in non-B carriers (P <0.001). TDR showed a slight, although not significant, decline (from 16.3% in 1996-2001 to 13.4% in 2006-07, P = 0.15); TDR declined for nucleoside reverse transcriptase inhibitors (from 13.1% to 8.2%, P = 0.003) but remained stable for protease inhibitors (from 3.7% to 2.5%, P = 0.12) and non-nucleoside reverse transcriptase inhibitors (from 3.7% to 5.8%). TDR to any drug was stable in B subtype and showed a decline trend in non-B. In multivariable analysis, F1 subtype or any non-B subtype, compared with B subtype, and higher HIV RNA were independent predictors of reduced odds of TDR. Conclusions: Prevalence of TDR to nucleoside reverse transcriptase inhibitors seems to have declined in Italy over time. Increased prevalence of non-B subtypes partially justifies this phenomenon.

KW - Decline

KW - Drug-naive

KW - Subtype

UR - http://www.scopus.com/inward/record.url?scp=69049092009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69049092009&partnerID=8YFLogxK

U2 - 10.1093/jac/dkp246

DO - 10.1093/jac/dkp246

M3 - Article

VL - 64

SP - 607

EP - 615

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

ER -